Just today, this drug became more widely available. Some product is now facing a recall following an apparent storage error.

A batch of the drug is under a limited voluntary recall after a shipping error exposed certain doses to improper temperatures.

NVO's first-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially ...

Seizures of potentially dangerous weight loss drugs being sold on the black market in Scotland have soared as online dealers ...

Novo Nordisk will continue offering its top-selling insulin brand, Mixtard, in vial form in India, despite phasing out ...

In a move which could shake up the diabetes market, Novo Nordisk is discontinuing the country’s largest selling insulin, ...

Eli Lilly Takes on Novo Nordisk with Orforglipron, an Oral Drug for Diabetes and Obesity That Could Change the Market. FDA ...

Danish pharmaceutical giant Novo Nordisk has announced plans to phase out Human Mixtard, India's top-selling insulin brand.

Novo Nordisk has said it is discontinuing selling its popular, best-selling insulin brand in India and will instead promote ...

Novo Nordisk will discontinue Human Mixtard, a top-selling insulin in India. This decision aligns with the company's global ...

If you’ve been using GLP-1 injectable medications like semaglutide and tirzepatide, what have you been doing with those used ...

Lilly also states that vial forms are cheaper than the auto-injector pre-filled pens. It also means you ... What is the difference between Ozempic and Zepbound? Zepbound and Ozempic both belong ...